Literature DB >> 20063437

GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex.

Vsevolod Katritch1, Manuel Rueda, Polo Chun-Hung Lam, Mark Yeager, Ruben Abagyan.   

Abstract

Proteins of the G-protein coupled receptor (GPCR) family present numerous attractive targets for rational drug design, but also a formidable challenge for identification and conformational modeling of their 3D structure. A recently performed assessment of blind predictions of adenosine A2a receptor (AA2AR) structure in complex with ZM241385 (ZMA) antagonist provided a first example of unbiased evaluation of the current modeling algorithms on a GPCR target with approximately 30% sequence identity to the closest structural template. Several of the 29 groups participating in this assessment exercise (Michino et al., doi: 10.1038/nrd2877) successfully predicted the overall position of the ligand ZMA in the AA2AR ligand binding pocket, however models from only three groups captured more than 40% the ligand-receptor contacts. Here we describe two of these top performing approaches, in which all-atom models of the AA2AR were generated by homology modeling followed by ligand guided backbone ensemble receptor optimization (LiBERO). The resulting AA2AR-ZMA models, along with the best models from other groups are assessed here for their vitual ligand screening (VLS) performance on a large set of GPCR ligands. We show that ligand guided optimization was critical for improvement of both ligand-receptor contacts and VLS performance as compared to the initial raw homology models. The best blindly predicted models performed on par with the crystal structure of AA2AR in selecting known antagonists from decoys, as well as from antagonists for other adenosine subtypes and AA2AR agonists. These results suggest that despite certain inaccuracies, the optimized homology models can be useful in the drug discovery process. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20063437      PMCID: PMC2805832          DOI: 10.1002/prot.22507

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  48 in total

1.  GPCR structure-based virtual screening approach for CB2 antagonist search.

Authors:  Jian-Zhong Chen; Junmei Wang; Xiang-Qun Xie
Journal:  J Chem Inf Model       Date:  2007-06-20       Impact factor: 4.956

Review 2.  Insights for the development of specific kinase inhibitors by targeted structural genomics.

Authors:  Oleg Fedorov; Michael Sundström; Brian Marsden; Stefan Knapp
Journal:  Drug Discov Today       Date:  2007-03-29       Impact factor: 7.851

Review 3.  A2A adenosine receptor and its modulators: overview on a druggable GPCR and on structure-activity relationship analysis and binding requirements of agonists and antagonists.

Authors:  G Cristalli; C Lambertucci; G Marucci; R Volpini; D Dal Ben
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 4.  GPCR agonists and antagonists in the clinic.

Authors:  Joel D A Tyndall; Radhika Sandilya
Journal:  Med Chem       Date:  2005-07       Impact factor: 2.745

Review 5.  The 7 TM G-protein-coupled receptor target family.

Authors:  Edgar Jacoby; Rochdi Bouhelal; Marc Gerspacher; Klaus Seuwen
Journal:  ChemMedChem       Date:  2006-08       Impact factor: 3.466

6.  Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.

Authors:  Vsevolod Katritch; Kimberly A Reynolds; Vadim Cherezov; Michael A Hanson; Christopher B Roth; Mark Yeager; Ruben Abagyan
Journal:  J Mol Recognit       Date:  2009 Jul-Aug       Impact factor: 2.137

7.  Consistent improvement of cross-docking results using binding site ensembles generated with elastic network normal modes.

Authors:  Manuel Rueda; Giovanni Bottegoni; Ruben Abagyan
Journal:  J Chem Inf Model       Date:  2009-03       Impact factor: 4.956

8.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

Review 9.  New G-protein-coupled receptor crystal structures: insights and limitations.

Authors:  Brian Kobilka; Gebhard F X Schertler
Journal:  Trends Pharmacol Sci       Date:  2008-01-14       Impact factor: 14.819

10.  Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile.

Authors:  Barbara Cacciari; Chiara Bolcato; Giampiero Spalluto; Karl-Norbet Klotz; Magdalena Bacilieri; Francesca Deflorian; Stefano Moro
Journal:  Purinergic Signal       Date:  2006-11-14       Impact factor: 3.765

View more
  55 in total

1.  Molecular mechanism of serotonin transporter inhibition elucidated by a new flexible docking protocol.

Authors:  Mari Gabrielsen; Rafał Kurczab; Aina W Ravna; Irina Kufareva; Ruben Abagyan; Zdzisław Chilmonczyk; Andrzej J Bojarski; Ingebrigt Sylte
Journal:  Eur J Med Chem       Date:  2011-10-20       Impact factor: 6.514

2.  Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4.

Authors:  Michael M Mysinger; Dahlia R Weiss; Joshua J Ziarek; Stéphanie Gravel; Allison K Doak; Joel Karpiak; Nikolaus Heveker; Brian K Shoichet; Brian F Volkman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 3.  New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi
Journal:  Mol Pharmacol       Date:  2012-06-13       Impact factor: 4.436

4.  Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach.

Authors:  Marco A C Neves; Sérgio Simões; M Luisa Sá e Melo
Journal:  J Comput Aided Mol Des       Date:  2010-10-20       Impact factor: 3.686

Review 5.  Identifying ligands at orphan GPCRs: current status using structure-based approaches.

Authors:  Tony Ngo; Irina Kufareva; James Lj Coleman; Robert M Graham; Ruben Abagyan; Nicola J Smith
Journal:  Br J Pharmacol       Date:  2016-03-05       Impact factor: 8.739

6.  Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening?

Authors:  Hao Tang; Xiang Simon Wang; Jui-Hua Hsieh; Alexander Tropsha
Journal:  Proteins       Date:  2012-03-13

7.  Simplified modeling approach suggests structural mechanisms for constitutive activation of the C5a receptor.

Authors:  Gregory V Nikiforovich; Garland R Marshall; Thomas J Baranski
Journal:  Proteins       Date:  2010-11-30

Review 8.  Computational methods in drug discovery.

Authors:  Gregory Sliwoski; Sandeepkumar Kothiwale; Jens Meiler; Edward W Lowe
Journal:  Pharmacol Rev       Date:  2013-12-31       Impact factor: 25.468

9.  The second extracellular loop of the adenosine A1 receptor mediates activity of allosteric enhancers.

Authors:  Dylan P Kennedy; Fiona M McRobb; Susan A Leonhardt; Michael Purdy; Heidi Figler; Melissa A Marshall; Mahendra Chordia; Robert Figler; Joel Linden; Ruben Abagyan; Mark Yeager
Journal:  Mol Pharmacol       Date:  2013-11-11       Impact factor: 4.436

10.  Exploring 3D structure of human gonadotropin hormone receptor at antagonist state using homology modeling, molecular dynamic simulation, and cross-docking studies.

Authors:  Amirhossein Sakhteman; Minasadat Khoddami; Manica Negahdaripour; Arash Mehdizadeh; Mohsen Tatar; Younes Ghasemi
Journal:  J Mol Model       Date:  2016-08-25       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.